BioAge Labs, Inc. announced the pricing of an upsized public offering of 5,897,435 shares of common stock at $19.50 per share, expected to raise approximately $115.0 million. The offering is set to close on January 23, 2026. The proceeds will fund research, development, and manufacturing of product candidates, including BGE-102 and NLRP3 and APJ programs. The underwriters have a 30-day option to purchase additional shares. Goldman Sachs & Co. LLC, Piper Sandler, and Citigroup are joint book-running managers. BioAge’s lead product candidate BGE-102 is undergoing Phase 1 trials, with additional data expected in 1H26. The Company is also developing treatments for obesity utilizing human longevity data.

Read more at GlobeNewswire: BioAge Announces Pricing of Upsized $115.0 Million Public